155 related articles for article (PubMed ID: 16312323)
1. Serum bactericidal activity against aerobes and anaerobes of volunteers receiving cefoxitin or cefotetan.
Cruciani M; Navarra A; Bono L; Concia E
J Chemother; 1989 Jul; 1(4 Suppl):101-2. PubMed ID: 16312323
[No Abstract] [Full Text] [Related]
2. Serum bactericidal activity against aerobes and anaerobes of volunteers receiving cefoxitin or cefotetan.
Cruciani M; Navarra A; Bono L; Concia E
Chemioterapia; 1988 Aug; 7(4):261-3. PubMed ID: 3180306
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro study of the antibacterial effect of cefotetan against gram-positive and gram-negative aerobic and anaerobic strains from fresh clinical isolates.
Klietmann W; Focht J; Nösner K
Chemioterapia; 1987 Jun; 6(2 Suppl):92-3. PubMed ID: 3509542
[No Abstract] [Full Text] [Related]
4. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
Edmiston CE; Krepel CJ; Clausz JC; Condon RE
Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
[TBL] [Abstract][Full Text] [Related]
5. [Sensitivity tests to antibiotics for aerobes and anaerobes in clinical practice].
Brenciaglia MI; Rivanera D; Lilli D; Filadoro F
Nuovi Ann Ig Microbiol; 1982; 33(2-3):349-74. PubMed ID: 7187036
[No Abstract] [Full Text] [Related]
6. Comparative in vitro activity of cefoxitin vs. cefotetan against clinical isolates of Bacteroides and Prevotella species.
Grossmeyer TJ; Farmer SG
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S353-6. PubMed ID: 8324146
[No Abstract] [Full Text] [Related]
7. Cefotetan versus cefoxitin in the treatment of patients with biliary sepsis assessed by a biliary sepsis score.
Basoli A; Schietroma M; Fiocca F; Vigliardi G; Speranza V
J Chemother; 1989 Jul; 1(4 Suppl):825-7. PubMed ID: 16312657
[No Abstract] [Full Text] [Related]
8. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.
Stein GE; Schooley S; Tyrrell KL; Citron DM; Nicolau DP; Goldstein EJ
Anaerobe; 2008 Feb; 14(1):8-12. PubMed ID: 17983770
[TBL] [Abstract][Full Text] [Related]
9. In vitro antibacterial activity of cefotetan against Bacteroides fragilis group clinical isolates.
Menozzi M; Avanzini P; Lecchini R; Bigi M; Chezzi C
Chemioterapia; 1987 Jun; 6(2 Suppl):88-91. PubMed ID: 3509541
[No Abstract] [Full Text] [Related]
10. [Reducing bacterial aerosols by ultrasonic scaling with Koutai or 1.5% H2O2 pre-rinse].
Chen H
Zhonghua Kou Qiang Yi Xue Za Zhi; 2000 Sep; 35(5):381-2. PubMed ID: 11780251
[TBL] [Abstract][Full Text] [Related]
11. Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis.
Goldstein EJ; Citron DM; Merriam CV; Abramson MA
Surg Infect (Larchmt); 2009 Apr; 10(2):111-8. PubMed ID: 19226203
[TBL] [Abstract][Full Text] [Related]
12. In vitro antibacterial activity of cefoxitin and cefotetan and pharmacokinetics in dogs.
Petersen SW; Rosin E
Am J Vet Res; 1993 Sep; 54(9):1496-9. PubMed ID: 8239139
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez HT
Antimicrob Agents Chemother; 2006 Aug; 50(8):2875-9. PubMed ID: 16870792
[TBL] [Abstract][Full Text] [Related]
14. [Incidence of cefotetan sensitivity in anaerobic microbes responsible for acute and chronic relapsing bronchopneumonia].
Guarino C; Cautiero V; Tarantino C; Cuccurullo S; Cione B; Marcatili A
G Ital Chemioter; 1989; 36(1-3):53-6. PubMed ID: 2488913
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic susceptibility of bacterial isolates in gingivitis and periodontitis.
Saini S; Aparna ; Gupta N; Mahajan A; Saini OP
Indian J Dent Res; 2003; 14(2):95-100. PubMed ID: 14705453
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
[TBL] [Abstract][Full Text] [Related]
17. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.
Wybo I; Piérard D; Verschraegen I; Reynders M; Vandoorslaer K; Claeys G; Delmée M; Glupczynski Y; Gordts B; Ieven M; Melin P; Struelens M; Verhaegen J; Lauwers S
J Antimicrob Chemother; 2007 Jan; 59(1):132-9. PubMed ID: 17095529
[TBL] [Abstract][Full Text] [Related]
18. Association experiments in antimicrobial susceptibility testing of aerobes and anaerobes to ampicillin and ampicillin plus sulbactam.
Heizmann WR; Werner H; Heilmann F
J Chemother; 1989 Jul; 1(4 Suppl):315-6. PubMed ID: 16312418
[No Abstract] [Full Text] [Related]
19. Cefoxitin in the treatment of aerobic and anaerobic infections. Prospective correlation of in vitro susceptibility methods with clinical outcome.
Goldstein EJ; Citron DM; Cole RE; Rangel DM; Seid AS; Ostovari MO
Hosp Pract (Off Ed); 1990 Oct; 25 Suppl 4():38-45. PubMed ID: 2120272
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.
Carver PL; Nightingale CH; Quintiliani R
J Antimicrob Chemother; 1989 Jan; 23(1):99-106. PubMed ID: 2745258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
